Prescient Therapeutics Ltd
PTX
Company Profile
Business description
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Contact
Level 4, 100 Albert Road
South Melbourne
MelbourneVIC3205
AUST: +61 396927222
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
1
Stocks News & Analysis
stocks
Stock showdown: How do ASX healthcare giants compare on key investing criteria?
Our healthcare analyst Shane Ponraj helps me compare the moatiness and growth prospects of two sector heavyweights.
stocks
Distribution growth for ASX income play
Cost containment and growing revenue bode well for profit margins.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,284.20 | 51.60 | 0.56% |
| CAC 40 | 7,938.29 | 34.74 | -0.44% |
| DAX 40 | 24,293.34 | 16.37 | 0.07% |
| Dow JONES (US) | 44,813.85 | 124.46 | -0.28% |
| FTSE 100 | 9,309.20 | 21.06 | 0.23% |
| HKSE | 25,104.61 | 61.33 | -0.24% |
| NASDAQ | 21,094.08 | 78.78 | -0.37% |
| Nikkei 225 | 42,610.17 | 278.38 | -0.65% |
| NZX 50 Index | 13,194.07 | 122.77 | 0.94% |
| S&P 500 | 6,374.90 | 20.88 | -0.33% |
| S&P/ASX 200 | 9,019.10 | 45.40 | 0.51% |
| SSE Composite Index | 3,771.10 | 4.89 | 0.13% |